LMAT Stock Analysis: LeMaitre Vascular | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 1.806m USD | 12M Return: -8.7% | US5255582018 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 21.6M
EPS Trend: 99.2%
Qual. Beats: -1
Rev. Trend: 99.9%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a U.S.-based medical device manufacturer specializing in surgical implants and instruments used in vascular surgery, with operations spanning the Americas, Europe, the Middle East, Africa, and Asia Pacific. The companys product portfolio is diverse and clinically focused, spanning catheters (embolectomy, thrombectomy, occlusion, and perfusion), biologic grafts and patches, vascular grafts, carotid shunts, valvulotomes, and closure systems, along with cryopreserved human tissue services. It markets its products through a combination of direct sales representatives and third-party distributors, and is headquartered in Burlington, Massachusetts, having been incorporated in 1983 (originally as Vascutech, Inc., before adopting its current name in April 2001).
The companys offerings reflect the fragmented nature of the vascular surgery device market, where single-vendor solutions are rare and product breadth across multiple clinical applications-dialysis access, peripheral bypass, varicose vein treatment, and cardiac repair-provides competitive insulation. Its inclusion of biologic and cryopreserved allograft products is notable, as these tissue-based offerings typically require specialized storage, donor screening, and regulatory compliance that differ from conventional manufactured implants, adding operational complexity but also differentiation within the broader Health Care Equipment sub-industry.
- XenoSure biologic patch sales accelerate high-margin growth
- European FX headwinds pressure reported revenue
- Tuck-in M&A expands vascular surgery product portfolio
| Net Income: 65.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 1.63 > 1.0 |
| NWC/Revenue: 174.7% < 20% (prev 170.2%; Δ 4.48% < -1%) |
| CFO/TA 0.13 > 3% & CFO 83.0m > Net Income 65.7m |
| Net Debt (-164.8m) to EBITDA (97.3m): -1.69 < 3 |
| Current Ratio: 16.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (24.5m) vs 12m ago 7.16% < -2% |
| Gross Margin: 72.90% > 18% (prev 69.11%; Δ 3.79% > 0.5%) |
| Asset Turnover: 43.09% > 50% (prev 40.62%; Δ 2.46% > 0%) |
| Interest Coverage Ratio: 16.11 > 6 (EBIT TTM 83.7m / Interest Expense TTM 5.20m) |
| A: 0.72 (Total Current Assets 488.3m - Total Current Liabilities 29.9m) / Total Assets 640.5m |
| B: 0.32 (Retained Earnings 206.0m / Total Assets 640.5m) |
| C: 0.14 (EBIT TTM 83.7m / Avg Total Assets 609.1m) |
| D: 1.91 (Book Value of Equity 420.3m / Total Liabilities 220.2m) |
| Altman-Z'' = 8.67 = AAA |
| DSRI: 0.87 (Receivables 35.7m/36.5m, Revenue 262.4m/234.6m) |
| GMI: 0.95 (GM 69.11% / 72.90%) |
| AQI: 0.88 (AQ_t 0.16 / AQ_t-1 0.18) |
| SGI: 1.12 (Revenue 262.4m / 234.6m) |
| TATA: -0.03 (NI 65.7m - CFO 83.0m) / TA 640.5m) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of October 07, 2026, the stock is trading at USD 79.05 with a total of 283,354 shares traded. Over the past week, the price has changed by -4.63%, over one month by -0.68%, over three months by -23.56% and over the past year by -8.73%.
Current recommended Stop Loss: 76.20 (which is 3.6% or 1.3 ATR below the current price).
LeMaitre Vascular has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold LMAT.
- StrongBuy: 2
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 107 | 35.4% |
P/E Trailing = 27.6084
P/E Forward = 25.5754
P/S = 6.8809
P/B = 4.3824
P/EG = 2.131
Revenue TTM = 262.4m USD
EBIT TTM = 83.7m USD
EBITDA TTM = 97.3m USD
Long Term Debt = 169.1m USD (from longTermDebt, last quarter)
Short Term Debt = 3.44m USD (from shortTermDebt, last quarter)
Debt = 211.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 21.2m
Net Debt = -164.8m USD (calculated: Debt 211.4m - CCE 376.2m)
Enterprise Value = 1.64b USD (1.81b + Debt 211.4m - CCE 376.2m)
Interest Coverage Ratio = 16.11 (Ebit TTM 83.7m / Interest Expense TTM 5.20m)
EV/FCF = 21.91x (Enterprise Value 1.64b / FCF TTM 74.9m)
FCF Yield = 4.56% (FCF TTM 74.9m / Enterprise Value 1.64b)
FCF Margin = 28.53% (FCF TTM 74.9m / Revenue TTM 262.4m)
Net Margin = 25.02% (Net Income TTM 65.7m / Revenue TTM 262.4m)
Gross Margin = 72.90% ((Revenue TTM 262.4m - Cost of Revenue TTM 71.1m) / Revenue TTM)
Gross Margin QoQ = 72.13% (prev 72.72%)
Tobins Q-Ratio = 2.56 (Enterprise Value 1.64b / Total Assets 640.5m)
Interest Expense / Debt = 2.46% (Interest Expense 5.20m / Debt 211.4m)
Taxrate = 22.50% (19.1m / 84.7m)
NOPAT = 64.9m (EBIT 83.7m * (1 - 22.50%))
Current Ratio = 14.72 (Total Current Assets 488.3m / Total Current Liabilities 33.2m)
Debt / Equity = 0.50 (Debt 211.4m / totalStockholderEquity, last quarter 420.3m)
Debt / EBITDA = -1.69 (Net Debt -164.8m / EBITDA 97.3m)
Debt / FCF = -2.20 (Net Debt -164.8m / FCF TTM 74.9m)
Total Stockholder Equity = 399.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.78% (Net Income 65.7m / Total Assets 640.5m)
RoE = 16.42% (Net Income TTM 65.7m / Total Stockholder Equity 399.9m)
RoCE = 14.72% (EBIT 83.7m / Capital Employed (Equity 399.9m + L.T.Debt 169.1m))
RoIC = 10.80% (NOPAT 64.9m / Invested Capital 600.9m)
WACC = 5.59% (E(1.81b)/V(2.02b) * Re(6.02%) + D(211.4m)/V(2.02b) * Rd(2.46%) * (1-Tc(0.22)))
Discount Rate = 6.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 63.69 | Cagr: 3.46%
[DCF] Terminal Value 77.97% ; FCFF base≈68.2m ; Y1≈78.2m ; Y5≈115.0m
[DCF] Fair Price = 82.89 (EV 1.73b - Net Debt -164.8m = Equity 1.90b / Shares 22.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.18 | EPS CAGR: 34.39% | SUE: -1.09 | # QB: -1
Revenue Correlation: 99.92 | Revenue CAGR: 13.43% | SUE: -0.93 | # QB: -1
EPS current Quarter (2026-09-30): EPS=0.69 | Chg30d=+0.00% | Revisions=-73% | Analysts=8
EPS current Year (2026-12-31): EPS=2.88 | Chg30d=+0.00% | Revisions=-73% | GrowthEPS=+14.2% | GrowthRev=+10.8%
EPS next Year (2027-12-31): EPS=3.18 | Chg30d=+0.00% | Revisions=-70% | GrowthEPS=+10.4% | GrowthRev=+9.5%
[Analyst] Revisions Ratio: -88% (up=0, down=23)